A$4.78 million R&D tax rebate received by Amplia Therapeutics
Amplia Therapeutics (ASX: ATX) has received A$4,778,235.52 via the Research and Development Tax Incentive from the Australian Tax Office. The R&D tax rebate relates to the financial year ended 31 March 2026.
The funds are non-dilutive, meaning they arrive without the company issuing new equity. For investors, that distinguishes the rebate from a capital raise.
The refund relates to expenditure on the company’s FAK inhibitors, narmafotinib (AMP945) and AMP886. These activities primarily related to the ongoing clinical trials of narmafotinib in advanced pancreatic cancer patients.
Stated use of funds
The funds will contribute to the further progression of both the ACCENT and AMPLICITY clinical trials of narmafotinib, along with the ACCENT-MINI Trial, the PRROSE Study, the Lilly combination studies and additional supporting R&D activities.
When big ASX news breaks, our subscribers know first
How the R&D Tax Incentive works
The Australian Government’s Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities. For a clinical-stage biotech, the refund returns a portion of trial spending as cash.
- What it is: A government program encouraging businesses to undertake R&D activities.
- Who it is for: Eligible companies carrying out R&D.
- What is refundable: A tax offset of 43.5%-48.5% (refundable) on eligible expenditure on R&D activities.
The announcement does not disclose Amplia’s specific offset rate or its eligible expenditure total.
Where the funds are going
The announcement states the funds will contribute to the following programs:
- ACCENT clinical trial of narmafotinib
- AMPLICITY clinical trial of narmafotinib
- ACCENT-MINI Trial
- PRROSE Study
- Lilly combination studies
- Additional supporting R&D activities
The table below summarises the key facts. No dollar allocations per trial were disclosed.
| Item | Detail |
|---|---|
| Rebate amount | A$4,778,235.52 |
| Period | Year ended 31 March 2026 |
| Use of funds | ACCENT, AMPLICITY, ACCENT-MINI, PRROSE, Lilly combination studies and additional supporting R&D activities |
| Investor impact | Non-dilutive funding supporting trial progression |
Narmafotinib trial context
The company’s existing disclosures on narmafotinib, as described in the announcement, include the following:
- Narmafotinib (AMP945) is described as the company’s best-in-class inhibitor of the protein FAK, which is over-expressed in pancreatic cancer.
- ACCENT: Narmafotinib is dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The company states the trial has achieved its desired outcome with a response rate of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported.
- AMPLICITY: Being run at sites in Australia, this trial is investigating narmafotinib combined with the chemotherapy FOLFIRINOX in first-line patients with advanced pancreatic cancer.
These results were previously reported by the company and are not new with this announcement.
The ACCENT trial data presented at AACR 2026 included an independently verified complete response rate roughly 40 times higher than chemotherapy alone, which underpins the company’s case for continued investment in the program.
The rebate supports continued progression across the narmafotinib clinical program and the related studies named by the company.
Ready to Learn More About Amplia’s Narmafotinib Pancreatic Cancer Program?
Amplia Therapeutics has received a non-dilutive $4.78 million R&D tax rebate to help advance narmafotinib through the ACCENT, AMPLICITY and related clinical trials. With ACCENT already reporting a 36% response rate in advanced pancreatic cancer, the funding supports a program with growing clinical momentum.
Investors seeking deeper insight into the pipeline and trial progress can visit the Amplia Therapeutics website for the latest company updates. Explore the narmafotinib program and see how it is shaping Amplia’s investment case.